MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.
Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P. · 2018
Read MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. by Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5941496.txt.
Introduction
Amodio and co-authors review MALAT1, a long non-coding RNA, as a drug target in cancer. Their review appeared in the Journal of Hematology & Oncology. Long non-coding RNAs were once dismissed as junk material. Research now shows they hold pivotal roles in cell biology. They make up more than half of the non-coding transcriptome. MALAT1 is abundant, conserved, and the best characterized of them.
The review sums up MALAT1 expression and function in cancer. Its activity goes off track in many human malignancies, the authors report. That pattern makes MALAT1 a candidate for targeted treatment. Blocking it could offer a new way to attack cancer. The authors set out the evidence and the open questions.
Catalog record
| CREATOR | Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 104 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches By Nicola Amodio, Lavinia Raimondi, Giada Juli, Maria Angelica Stamato, Daniele Caracciolo, Pierosandro Tagliaferri, Pierfrancesco Tassone Published in: Journal of Hematology & Oncology DOI: 10.1186/s13045-018-0606-4 ABSTRACT Abstract The deeper understanding of non-coding RNAs has recently changed the dogma of molecular biology assuming protein-coding genes as unique functional biological effectors, while non-coding genes as junk material of doubtful significance. In the last decade, an exciting boom of experimental research has brought to light the pivotal biological functions of long non-coding RNAs (lncRNAs), representing more than the half of the whole non-coding transcriptome, along with their dysregulation in many diseases, including cancer. In this review, we summarize the emerging insights on lncRNA expression and functional role in cancer, focusing on the evolutionary conserved and abundantly expressed metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) that currently represents the best characterized lncRNA. Altogether, literature data indicate aberrant expression and dysregulated activity of MALAT1 in human malignancies and envision MALAT1 targeting as a novel treatment strategy against cancer. Keywords: MALAT1, Long non-coding RNA, lncRNA, Non-coding RNA, Epigenetics, Experimental therapeutics BACKGROUND Long non-coding RNAs (lncRNAs): classification and mechanisms of action Deep analysis of the human transcriptome has estimated that while three quarters of the human genome is actively transcribed, only the 3% is represented by protein-coding genes. While such a huge non-coding genome was considered transcriptional noise and neglected until the last decade, its biological relevance is nowadays well-acknowledged and represents a matter of intense investigation. Different types of classification for non-coding RNAs (ncRNAs) have been so far adopted. Based on their length, ncRNAs can be classified into short (< 200 nucleotides) or lncRNAs (> 200 nucleotides) [1]. LncRNAs are the most abundant class of ncRNAs involved in important biological processes, such as epigenetic control of gene expression, promoter-specific transcriptional regulation [2], X chromosome inactivation [3, 4], genomic imprinting [5, 6], and cell differentiation and development [7]; consistent with a role in these processes, it is not surprising that lncRNAs are found dysregulated in different human diseases, including cancer [8]. Overall, these RNA molecules do not show protein-coding potential, localize predominantly to the nucleus, and are generally less expressed than protein-coding genes, while displaying more tissue-specific expression patterns; moreover, lncRNAs generally undergo splicing and can be polyadenylated [1, 9]. Based on molecular function, lncRNAs can be distinguished in the following: - lncRNAs signal that regulate the transcription by interacting with transcription factors (TFs), and activate or repress their activity; - lncRNAs decoy that displace TFs and other proteins from chromatin of which they are negative regulators; - lncRNAs scaffold that bind multiple proteins and facilitate the formation of ribonucleoprotein complexes; - lncRNAs guide, acting as guidance molecules for chromatin-modifying protein complexes to target genes [10]. While cis-acting RNAs are limited to the site of synthesis and operate on one or more genes on the same chromosome, trans-acting RNAs move from the site of synthesis and exert their function at larger distances or even on other chromosomes [11]. Moreover, lncRNAs can modulate the mRNA life cycle in the cytoplasm through different mechanisms, including the following: - mRNA stability regulation by Staufen 1 (STAU1)-mediated decay, in which base-pairing of ALU elements located in the lncRNA and the target mRNA creates a double-stranded STAU1-binding site that can direct exosome mediated RNA degradation [12]; - RNA splicing regulation by direct association between lncRNAs and splicing factors; - RNA editing regulation with activation of ADAR enzymes induced by the interaction of antisense lncRNA and sense mRNA [11]; - miRNA sponges that contain multiple binding sites for one or more miRNAs and regulate target mRNA expression by sequestering miRNAs away from their mRNA targets [13, 14]. LncRNAs can be also classified according to their genomic location with respect to the nearest protein-coding genes. In this regard: - Long intergenic non-coding RNAs (lincRNAs) are ncRNAs which do not lie close to protein-coding genes; - Sense lncRNAs are on the same strand of protein-coding genes and are transcribed in the same direction; - Antisense lncRNAs lie on the opposite strand of protein-coding genes with which they overlap (if the overlap is partial, lncRNAs are defined natural antisense transcripts); - Intronic antisense lncRNAs and bidirectional lncRNAs that locate on the other strand with respect to protein-coding genes and are transcribed in the opposite direction [15, 16]. Several lncRNA databases providing relevant information on lncRNA structure and functional role are currently available. Noteworthy, LNCipedia annotates human lncRNA sequences and structures [17], while lncRNAdb contains information about lncRNA biological functions and expression in different biological systems [18]. The GENCODE consortium includes human genome annotation for the ENCODE project [19], while the NONCODE database (v3.0 and 4.0) has extended available information on lncRNA cellular localization, function and expression to the cancer setting [20, 21]. For in-depth information on lncRNA databases, we recommend to the readers more specialized reviews [22]. Cancer-related mechanisms of lncRNA dysregulation LncRNAs have emerged as novel master regulators of initiation, progression, and response to therapy in a wide variety of solid tumors and hematological malignancies. Compelling evidence supports aberrant patterns of expression of lncRNAs in cancer [16], which may occur through various mechanisms, summarized in Table 1. [Table: Mechanisms involved in dysregulated expression of the most relevant cancer-associated lncRNAs] Genomic alterations Deletions or amplification of gene loci may be responsible of abnormal expression of lncRNAs in cancer. Deleted in leukemia 1 (DLEU1) and 2 (DLEU2) are two lncRNAs whose genes map in a critical region at chromosome 13q14.3 deleted in more than 50% of chronic lymphocytic leukemia (CLL) patients [23], and hosting miR-15a and 16–1, a miRNA tumor suppressive cluster [24]. Mice deleted for the entire minimal deleted region within 13q14, comprising DLEU2 gene, developed clonal B cell proliferations resembling human CLL [25, 26]. LncRNA expression profiling of the major forms of plasma cell dyscrasias highlighted significant downregulation of DLEU2 in patients carrying del13 [27]. Amplification at 8q24 locus, which correlated with reduced overall survival of breast and ovarian cancer patients, was responsible of increased expression of the lncRNA PVT1, whose in vitro inhibition triggered apoptosis and reduced survival of cancer cell lines [28]. The presence of tumor-associated single nucleotides polymorphisms (SNPs) within enhancer regions of certain lncRNAs, including HOTAIR, may also drive their dysregulated expression and was found to correlate with high risk of tumor development [29]. Epigenetic alterations Epigenetic modifications account for aberrant expression of short ncRNAs [30], but are also implicated in lncRNA dysregulation. Zhang and colleagues integrated multi-omics data to assess alterations of lncRNA methylation in breast invasive carcinoma, highlighting abnormally methylated lncRNAs involved in several hallmarks of cancers [31]. In multiple myeloma (MM) cells, the methylation of promoter-associated CpG islands triggered downregulation of KIAA0495, a lncRNA transcribed from chromosome 1p36 [32]; CpG island hypermethylation also downregulated the KIAA0495/p53-dependent apoptotic modulator PDAM, which in turn established a drug resistant phenotype in glioma cells [33]. Aberrant promoter methylation of the imprinted lncRNA gene MEG3 was described in acute myeloid leukemia and myelodysplastic syndromes patients, where MEG3 methylation status negatively correlated with overall survival [34]; MEG3 promoter hyper-methylation has been also reported in MM [35] and in esophageal squamous cell carcinoma (ESCC) [36]. P53-dependent regulation Several factors involved in cellular homeostasis may regulate lncRNA